FGFR2 and cholangiocarcinoma: As with the Next-Generation Sequencing (NGS) assay, the latest National Comprehensive Cancer Network (NCCN) guidelines recommend it as a test for FGFR2 fusion/other FGFR aberrations in cholangiocarcinoma [77].